Alteration of p16 and p15 genes in human uterine tumours
Author Information
Author(s): Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, Buzard G, Murata Y
Primary Institution: Department of Obstetrics and Gynecology, Osaka University Faculty of Medicine
Hypothesis
The roles of the p16 and p15 inhibitor of cyclin-dependent kinase tumour suppressor genes were examined in human uterine cervical and endometrial cancers.
Conclusion
Inactivation of the p16 gene occurs in a subset of uterine tumours through various mechanisms.
Supporting Evidence
- p16 mRNA was significantly reduced in 26% of cervical and 16% of endometrial tumours.
- Reduced expression of p16 protein occurred in 27% of cervical and 19% of endometrial tumours.
- Hypermethylation of the p16 gene was detected in only 3% of cervical tumours.
- Homozygous p16 gene deletion was found in 10% of cervical and 3% of endometrial tumours.
- Homozygous deletion of p15 was found in 8% of cervical and 3% of endometrial tumours.
- Point mutations in the p16 gene were detected in 8% of uterine tumours.
Takeaway
This study looked at how certain genes related to cancer are changed in tumors from the uterus, finding that some tumors have problems with the p16 gene.
Methodology
The study used RT-PCR, immunohistochemistry, differential PCR analysis, and PCR-SSCP to examine gene alterations.
Participant Demographics
The study included 40 cervical and 38 endometrial tumours.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website